• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library

    Ipsen’s Biologics Increlex Receives Suppl Approval in US

    FDA

    Ipsen Biopharma`s Iqirvo Receives Approval in Canada

    HEALTH CANADA

    Ipsen Pharma`s Iqirvo (elafibranor) Receives Approval in Europe

    EMA

    Ipsen Pharma`s Kayfanda (odevixibat) Receives Approval in Europe

    EMA

    Ipsen`s Biologic Increlex (mecasermin) Receives Approval in the U.S.

    FDA

    Ipsen`s Biologic Increlex (mecasermin) Receives Approval in the U.S.

    FDA

    Ipsen`s Biologic Dysport (AbobotulinumtoxinA) Receives Approval in the U.S.

    FDA

    Ipsen` Biologic DYSPORT (AbobotulinumtoxinA) Receives Approval in the U.S.

    FDA

    Ipsen Biopharm Dysport (abobotulinumtoxinA) Receives Supplemental Approval in US

    FDA

    Ipsen Biopharm Dysport (abobotulinumtoxinA) Receives Supplemental Approval in US

    FDA

    Ipsen Biopharm `s Biological Abobotulinumtoxina Receives Approval in US

    FDA

    Ipsen Pharma`s Xermelo (telotristat ethyl) Receives Approval In Europe

    EMA

    Ipsen Biopharm’s Dysport (Abobotulinumtoxina) Receives Supplemental

    FDA

    Ipsen`s Supplement Dysport (abobotulinumtoxinA) Receives Approval In US

    FDA

    Ipsen Pharma Cabometyx Approved In Europe

    EUROPE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.